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3ABSTRACT
Background/ Objectives
Lower-than-recommended doses of direct-acting oral anticoagulants are often 
prescribed to older adults with non-valvular atrial fibrillation (NVAF). Our goal was 
to determine the consequences of lower-than- recommended dosing on plasma 
apixaban concentrations during clinical care of older adults with NVAF. 
Design
Convenience sample of patients receiving anticoagulation during 2017
Setting
Academic medical center
Participants
Stable adults over age 65 years with non-valvular atrial fibrillation receiving 
apixaban on a chronic basis
Measurements
Patient age, weight, creatinine, co-medications, apixaban concentrations 
Results
One hundred and ten older adults with NVAF (mean age of 80.4 years, range 66-
100 with 45% women) were studied. Forty-eight patients received recommended 
dosing of 5 mg twice daily and 42 received lower-than-recommended dosing. One 
patient in each category had concentrations below expected 5-95% range at time 
of peak concentrations. Differences in proportion of apixaban concentrations within
or outside expected ranges were not significant between patients receiving lower-
than-recommended doses and those dosed-as-recommended at 5 mg twice daily 
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
4(p=0.35). However, in patients dosed-as-recommended with 5 mg twice daily, four 
had concentrations above 5-95% range for peak levels expected at 3-4 hours after 
dosing; in two, this occurred around the midpoint of the dosing interval. Twenty 
patients received 2.5 mg twice daily as recommended.  One third had apixaban 
concentrations higher than expected peak concentrations compared to the clinical 
trials and, over 2/3 had levels above the reported median for peak concentrations. 
Conclusions
Apixaban concentrations in older adults with NVAF seen clinically were higher than 
expected based on clinical trial data. The findings raise questions about the 
optimal dosing of apixaban in older adults with NVAF encountered outside of 
clinical trials and suggest a role for monitoring of apixaban concentrations during 
care of patients that differ from those in randomized trials, or when considering 
dosing outside of published guidelines.
Keywords: apixaban, direct-acting oral anticoagulant, non-valvular atrial fibrillation,
dosing accuracy, 
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5INTRODUCTION
Direct-acting oral anticoagulants (DOACs) are replacing vitamin K antagonists for 
anticoagulation due to fewer food and medication interactions and simplified dosing and 
monitoring regimens. 1  While DOACs have been shown to have equivalent or superior 
efficacy to prevent stroke or systemic emboli in patients with non-valvular atrial fibrillation
(NVAF) with fewer intracranial hemorrhages in randomized trials,2-4 there are limited data 
on older adults with NVAF during routine clinical care.  These patients are often older, 
more likely to be women, have more co-morbidities, falls, and higher bleeding risks than 
those enrolled in clinical trials.  Possibly due to these factors, post-marketing analyses 
of DOAC use in patients with NVAF report prescribed doses often inconsistent with 
product labelling. 1 Lower-than-recommended dosing is more common than higher-
than-recommended dosing, especially for apixaban in older patients.5,6 7,8 
The consequences of under-dosing are currently uncertain.   If under-dosing resulted in 
lower apixaban concentrations, increased stroke rates would be expected, as would lower 
bleeding rates.  Analyses from administrative claims data lacking full assessment of 
dosing accuracy reported increased stroke rates without increased bleeding in patients 
with NVAF receiving apixaban classified as “under-dosed”.  7  Under-dosing was also 
initially reported to result in worse outcomes  in patients enrolled in The Outcomes 
Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF) registry. 9 
However, when the outcomes were adjusted for patient risk characteristics, no significant 
difference in outcomes between “under-dosed” patients compared to patients dosed as 
recommended was detected in the ORBIT-AF registry. 10  These studies did not determine 
drug concentrations in relation to dosing or outcomes to investigate potential mechanisms
for alterations in responses or outcomes.  
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6Our primary goal was to measure plasma apixaban concentrations during routine 
clinical care of older adults with NVAF and compare apixaban concentrations 
between patients receiving recommended vs. lower-than-recommended dosing 
relative to concentrations reported from the pivotal trial on which marketing 
approval was granted (ARISTOTLE trial). 11 We found that older adults with NVAF 
receiving lower than recommended dosing of apixaban had the same proportion of 
concentrations within the ranges reported from patients receiving recommended doses, 
and, only patients receiving recommended doses had concentrations in excess of those 
observed in clinical trials. 
METHODS
 Patients and Data Collection. Clinically stable older adults with NVAF taking 
apixaban and seen at least once at an anticoagulation clinic during 2017 were 
invited to participate in the study.  Written informed consent was obtained per 
protocol approved by the Health Sciences Research Ethics Board of the University 
of Western Ontario (London, Ontario, Canada). Patient age, sex, weight, height, 
apixaban dose regimen, concomitant use of moderate (amiodarone, diltiazem, 
fluconazole, verapamil) to strong (clarithromycin, ketoconazole, ritonavir) P-
gp/CYP3A4 inhibitors and P-gp/CYP3A4 inducers (carbamazepine, phenytoin, 
phenobarbital, rifampin) , most recent serum creatinine, and date/time of last 
apixaban dose were collected when single steady-state blood samples were 
obtained. Blood samples were immediately stored at -4ºC before centrifugation at 
2000g for 10 minutes for plasma isolation. Plasma samples were stored at -80ºC 
until further analysis. Apixaban concentrations were determined by liquid 
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7chromatography tandem mass spectrometry as previously reported. 12 Lower limit 
of quantitation is 5 ng/mL.  Assay performance across the 25, 250, and 1000 
ng/mL quality controls were 1.5% and 8.5%, intraday bias and precision was 1.3% 
and 5.1%.  
Data analysis. Dosing was categorized as recommended, higher-than, or lower-
than-recommended. Recommended apixaban dosing in 5 mg twice daily reduced 
to 2.5 mg twice daily with two of the following present: age > 80 y, weight < 60 
kg, serum creatinine > 1.5 mg/dL, or a strong CYP3A4/P-gp inhibitor is co-
administered without 2 of the 3 dose reduction criteria. 
(https://packageinserts.bms.com/pi/pi_eliquis.pdf). For patients meeting 
recommendations for 5 mg twice daily, apixaban concentrations were categorized 
as being within, higher, or lower than the expected 5-95% percentile at peak (91-
321 ng/mL, median =171 ng/mL) or trough (41-230 ng/mL, median =103 ng/mL ) 
compared to patients receiving 5 mg twice daily in the pivotal ARISTOTLE trial. 11 
For patients receiving 2.5 mg twice daily as recommended, concentrations were 
similarly categorized in reference to patients receiving 2.5 mg twice daily in 
ARISTOTLE ( peak: 69-221 ng/mL, 123 median; trough: 34-162 ng/mL, median  79 
ng/mL). Concentrations were analyzed in relation to dosing accuracy by Chi Square
RESULTS
One hundred ten patients were studied (see Table 1 for characteristics). No 
patients received higher- than-recommended dosing. Sixty-eight patients received 
recommended dosing: 5 mg twice daily in 48 (26 had one dose reduction criteria: 
age in 16, weight in 3, creatinine in 7), and 2.5 mg twice daily in 20 (age criteria in 
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8all; creatinine criteria in 13, weight criteria in 9 (two patients met all 3 dose 
reduction criteria).  Forty-two received lower-than-recommended dosing of 2.5 mg 
twice daily (29 had one dose reduction criteria: age in 21, weight in 2, creatinine in
6).  No patients received strong CYP3A4/5 P-gP inhibitors. 
Apixaban concentrations after dosing in patients receiving the recommended dose 
of 5 mg twice daily and those receiving lower than recommended dosing at 2.5 mg
twice daily are shown in Figure 1. One dosed as recommended and one dosed 
lower than recommended patient had concentrations below the expected 5-95% 
range at expected time of peak concentrations (91-321 ng/ml). In patients dosed-
as-recommended with 5 mg twice daily, four  (two older than age 90) had 
concentrations above expected 5-95% range at peak that occurred later than the 
reported 3-4 hours after dosing time of peak concentrations in two. Few patients 
were sampled at trough (12 hours after dosing) but none had concentrations below
expected 5-95% range at trough in either group. No significant differences in 
proportion of apixaban concentrations within or outside expected ranges were 
detected between patients receiving lower-than-recommended doses and those 
dosed as recommended (p=0.35).
Concentrations from patients receiving appropriately reduced doses were 
compared to data from ARISTOTLE participants receiving appropriately reduced 
doses. Concentration vs. time data  for these twenty patients receiving 2.5 mg 
twice daily as recommended are shown in Figure 2. Concentrations above the 5-
95% range for expected peak from ARISTOTLE data (69-221 ng/mL) were seen in 7
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9of the 20 as late as 7 hours after dosing.   Seventeen of the twenty had 
concentrations from 3 to 8.5 hours after dosing that were above the expected 
median peak level at 3-4 hours (123 ng/mL). 
  
DISCUSSION
Our goal was to determine apixaban concentrations in older and very old adults in 
the community being treated with apixaban for the prevention of stroke in the 
presence of non-valvular atrial fibrillation.  The mean age of patients studied in this
report is 80.4 years (range 66-100),  women represented 45% of the group, and 
one third received lower than recommended dosing.    There are several key 
observations from our study.  One is that patients receiving reduced dosages 
without meeting criteria for dosage reduction had apixaban concentrations within 
the ranges reported for the recommended doses.  A second point is that a low and 
similar proportion of concentrations below expected peak concentrations was seen
in patients receiving 2.5 mg twice daily without meeting criteria for dose 
reductions compared to patients receiving the recommended 5 mg twice daily.  
Third, only patients receiving recommended 5 mg twice daily dosing had 
concentrations far in excess of the expected 5-95% range for peak concentrations  
Numbers were small and the trend was not significant but raises concern as 
increasing apixaban concentrations produce greater anticoagulation and older 
adults are at higher basal risk for bleeding.  Fourth, patients receiving 
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appropriately reduced doses of 2.5 mg twice daily had concentrations greater than
patients receiving the 2.5 mg twice daily in the clinical trials.  Finally, the data also 
suggest that clinicians recognize characteristics of patients that may warrant 
dosage reductions from recommendations based on randomized clinical trials.
 
Current clinical dosing recommendations for DOACs reflect the regimens that were used 
in the efficacy trials on which marketing approval was granted.  For apixaban, 
recommended standard dosing is 5 mg twice daily reduced to 2.5 mg twice daily if 
the patient has two of the following characteristics: 80 years or older, weight of 60 
kg or below, creatinine of 1.5 mg/dL or above; or, is co-administered a strong 
CYP3A4/5 P-gP inhibitor. (https://packageinserts.bms.com/pi/pi_eliquis.pdf). Dosing 
with 2.5 mg twice daily in the absence of 2 of the 3 criteria represents a 50% 
reduction from recommendations. The algorithm appears to have been selected to 
account qualitatively for possible changes in drug distribution or clearance 
(without more precise estimates of creatinine clearance) or the increased risk of 
bleeding in the very elderly.   Most pivotal pre-marketing trials of DOACs did not 
report measurement of concentrations or anticoagulant effects and thus 
prescribing guidelines do not advocate laboratory monitoring of either DOAC 
concentrations or effects. However, DOAC concentrations are directly related to 
factor Xa inhibition and anticoagulation.  Data recently published from the earlier 
trials show dabigatran and edoxaban have a direct relationship between drug 
concentrations, factor Xa inhibition and efficacy as well as bleeding outcomes for 
the treatment of patients with NVAF. 13-15  Apixaban concentration data from NVAF 
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clinical trials have recently been analyzed and published but have not been related
to clinical outcomes. 16,17  Clinical laboratories are establishing DOAC assays and 
report the concentration
data from the clinical trials as reference ranges.
Importantly, pivotal non-valvular atrial fibrillation trials enrolled patients with mean
age of 70 years, fewer women than men, almost no racial minorities, no patients 
on dialysis, resulting in only about 5% receiving the reduced dose. 18   This leaves a
critical deficiency of data on use of apixaban in the complex and heterogeneous 
population of older adults with NVAF.  Post-marketing registry studies or analyses 
of claims data have attempted to address this gap, and in general report equal 
efficacy in clinical populations to that seen during clinical trials. 7,9,10,19-22 However, 
major extracranial and GI bleeding rates were similar for warfarin and DOACs in 
NVAF trials.  Rates for major bleeding of 2.6-3.3% were reported for patients over 
age 75y in ARISTOTLE and were 4.5% per year for major and clinically relevant 
nonmajor bleeding in patients unsuitable for warfarin in AVERROES. 2,23,24 Major 
bleeding rates reported from administrative claims data are on the order of 4% -5%
per year for major bleeding 7,10 7 10,25 but range from 2.6 -10%. 7,10,26,27 28 No post-
marketing studies have analyzed either drug concentrations or factor Xa inhibition 
in relation to dosing or outcomes.   When doses are higher than recommended, 
major bleeding rates rise 7and have been reported as 6.9% 9.  We recognize our 
data are preliminary.  Our sample was not random and patients receiving 2.5 mg 
twice daily not meeting dose reduction criteria were likely oversampled. Patients 
were  seen or followed in a specialized anticoagulation clinic at a tertiary care 
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
12
medical center capable of monitoring apixaban concentrations as part of a 
research program.  We did not have outcomes data to relate the concentrations to 
either efficacy or adverse bleeding events but used the surrogate marker of drug 
concentration ranges reported from the clinical trials as the reference range by 
clinical laboratories that perform DOAC assaysWe also did not have information on 
reasons physicians prescribed lower than recommended dosing. Nonetheless, the 
data suggest that concentration responses to doses of apixaban in older patients 
encountered during routine clinical care may differ from the somewhat limited data
reported from clinical trials. 
There is a need for more information about prescribing, outcomes, as well as risks 
and benefits of DOAC use in the older patients with NVAF. 29Until such data are 
available, the clinician is faced with balancing the high risk of embolic stroke from 
NVAF with the high risk of bleeding. Clinical laboratories are establishing DOAC 
assays and laboratory monitoring may provide helpful information. 
CONCLUSION
Our findings raise questions about optimal dosing of apixaban in older adults with 
NVAF outside of clinical trials. Drug concentrations were higher than expected 
based on clinical trial data and should caution those who advocate that lower than 
recommended dosing be a target for correction.30  Clinical laboratories are 
establishing DOAC assays and report the concentration data from the clinical trials 
as reference ranges.  Our data support a role for monitoring factor Xa inhibition or 
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apixaban concentrations when treating patients that differ from those in 
randomized trials, or when considering dosing outside of published guidelines.
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LEGENDS
Figure 1. Apixaban concentrations after dosing in patients with recommended 
dosing of 5 mg twice daily. 
Apixaban concentrations after dosing are shown from patients receiving lower than
recommended dosing of 2.5 mg twice daily in red and those receiving 
recommended dosing of 5 mg twice daily in green. Dashed vertical lines indicate 
expected 5-95% range (and median) at peak (91-321 ng/mL at 3-4hrs after dosing,
median 171 ng/ml ) and trough (41-230 ng/mL, median 103 ng/mL at 12hrs after 
dosing).  
Figure  2. Apixaban concentrations after dosing in patients receiving 
recommended 2.4 mg twice daily.
Apixaban concentrations after dosing are shown from patients receiving 
recommended dosing of 2.5 mg twice daily Dashed vertical lines indicate expected
5-95% range (and median) at peak (69-221 ng/mL, median;123 ng/mL at 3-4hrs 
after dosing) and trough (34-162 ng/mL, median 79  ng/mL at 12hrs after dosing).  
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Table 1. Patient Characteristics and Apixaban Dosing
Dosed as 
Recommended
  
Dosed lower 
than 
Recommended
2.5 mg 
twice daily
5 mg twice
daily
2.5 mg twice 
daily
N 110 20 48 42
Age (y)
(range)
80.4± 7.8*
(66-100)
88.6 ±5.3
(80-100)
77.8 ±7.2
(66-96)
79.4 ±6.9
(67-96)
Sex (men, 
women)
60, 50 5, 15 33, 15 22, 20
Race White White White White
Weight (kg) 86.4 
±21.4
(44-140.3)
71.1±22.2
(45.8-
123.1)
94.6 
±19.7
(58-140.3)
83.9±18.6
(44-118.4)
Creatinine 
(mg/dL)
1.2±0.5
(0.6-2.7)
1.6 ±0.4
(0.8-2.7)
1.1 ±0.3
(0.6-2.0)
1.2±0.5
(0.6-2.7)
Creatinine 
Clearance 
(ml/min)
59 ± 27
14-143)
31 ± 15
(14-77)
68 ± 26
(35-143)
62 ± 24
(18-121)
Strong CYP3A4/5 
P-gP Inhibitors
0 0 0 0
Moderate 
CYP3A4/5 P-gP 
Inhibitors^
20 6 6 8
  Amiodarone 7 3 1 3
  Diltiazem 13 3 5 5
Strong Inducer
(carbamazepine)
1 0 0 1
*Data are mean ± SD, (range). ^ No dose adjustment recommended for moderate 
inhibitors. 
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